In vitro and in vivo antifungal susceptibilities of the mucoralean fungus Cunninghamella

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4550-4555

  Pastor, F Javier ^a   Ruíz Cendoya, Mery ^a   Pujol, Isabel ^a   Mayayo, Emilio ^a   Sutton, Deanna A ^b   Guarro, Josep ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CANADIOL; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BACTERIAL STRAIN; BRAIN; CONTROLLED STUDY; CUNNINGHAMELLA BERTHOLLETIAE; CUNNINGHAMELLA ECHINULATA; DIABETES MELLITUS; DRUG EFFICACY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUCORMYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CUNNINGHAMELLA; DIABETES MELLITUS, EXPERIMENTAL; ECHINOCANDINS; ITRACONAZOLE; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MUCORMYCOSIS; PYRIMIDINES; THIAZOLES; TRIAZOLES;

EID: 78049236495     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00786-10     Document Type: Article

References (23)

1. Alastruey-Izquierdo, A., M. V. Castelli, I. Cuesta, A. Monzon, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2009. Activity of posaconazole and other antifungal agents against Mucorales identified by means of ITS sequencing. Antimicrob. Agents Chemother. 53:1686-1689.
2. Almyroudis, N. G., D. A. Sutton, A. W. Fothergill, M. G. Rinaldi, and S. Kusne. 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51:2587-2590.
3. Alvarez, E., D. A. Sutton, J. Cano, A. W. Fothergill, A. Stchigel, M. G. Rinaldi, and J. Guarro. 2009. Spectrum of zygomycete species identified from clinically significant specimens in the United States. J. Clin. Microbiol. 47:1650-1656.
4. Bibashi, E., V. Sidi, M. Kotsiou, E. Makrigiannaki, and D. Koliouskas. 2008. Pulmonary zygomycosis caused by Cunninghamella bertholletiae in a child with acute lymphoblastic leukemia. Hippokratia 12:43-45.
5. Chayakulkeeree, M., M. A. Ghannoum, and J. R. Perfect. 2006. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25:215-229.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Dannaoui, E., J. F. G. M. Meis, D. Loebenberg, and P. E. Verweij. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47:3647-3650.
8. de Hoog, G. S., J. Guarro, J. Gené, and M. J. Figueras. 2000. Atlas of clinical fungi, 2nd ed. Centraalbureau voor Schimmelcultures, Utrecht, Netherlands.
9. Garbino, J., C. Myers, J. Ambrosioni, and F. Gumy-Pause. 2010. Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with GvHD and review of the literature. J. Pediatr. Hematol. Oncol. 32:83-84.
10. Greenberg, R. N., K. Mullane, J. A. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, M. Schuster, J. R. Wingard, C. E. Gonzalez, S. G. Revankar, G. Corcoran, R. J. Kryscio, and R. Hare. 2006. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50:126-133.
11. Honda, A., K. Kamei, H. Unno, K. Hiroshima, T. Kuriyama, and M. Miyaji. 1999. A murine model of zygomycosis by Cunninghamella bertholletiae. Mycopathologia 144:141-146.
12. Ibrahim, A. S., V. Avanessian, B. Spellberg, and J. E. Edwards, Jr. 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47:3343-3344.
13. Ibrahim, A. S., T. Gebremariam, J. A. Schwartz, J. E. Edwards, Jr., and B. Spellberg. 2009. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob. Agents Chemother. 53:772-775.
14. Ortoneda, M., J. Capilla, F. J. Pastor, C. Serena, and J. Guarro. 2004. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn. Microbiol. Infect. Dis. 50:247-251.
15. Passos, X. S., W. S. Sales, P. J. Maciel, C. R. Costa, D. M. Ferreira, and M. R. do Silva. 2006. Nosocomial invasive infection caused by Cunninghamella bertholletiae: case report. Mycopathologia 161:33-35.
16. Paul, S., F. M. Marty, and Y. L. Colson. 2006. Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. Ann. Thorac. Surg. 82:338-340.
17. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236-301.
18. Righi, E., C. G. Giacomazzi, V. Lindstrom, A. Albarello, O. Soro, M. Miglino, M. Perotti, O. E. Varnier, M. Gobbi, C. Viscoli, and M. Bassetti. 2008. A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies. Mycopathologia 165:407-410.
19. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
20. Rogers, T. R. 2008. Treatment of zygomycosis: current and new options. J. Antimicrob. Chemother. 61(Suppl. 1):i35-i40.
21. Rosen, D. A., C. S. Hung, K. A. Kline, and S. J. Hultgren. 2008. Streptozocininduced diabetic mouse model of urinary tract infection. Infect. Immun. 76:4290-4298.
22. Sun, Q., L. Najvar, R. Bocanegra, D. Loebenberg, and J. R. Graybill. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46:2310-2312.
23. van Burik, J. A., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:61-65.